A new breakthrough in JAK1 inhibitors! Ulcerative colitis new drug filgotinib reaches primary end point of test

Gilead and Galapagos recently announced all the main endpoints of the IIb/III study (SELECTION) on the treatment of moderate to severe active ulcerative colitis (UC) of the research JAK1 inhibitor filgotinib"We are encouraged by the early response of filgotinib as an induced therapy and its long-lasting efficacy as a maintenance therapy," said Merdad Parsey, Chief Medical Officer of GileadFilgotinib is expected to help an increasing number of patients achieve lasting treatment outcomes through oral therapy."the trial recruited 1,348 patients with moderate to severe active ulcerative colitis who were randomly classified into the filgotinib group or the placebo groupThe main endpoint is to evaluate the efficacy of filgotinib in treating rectal bleeding in UC patientsThe results showed that the 200 mg dose of filgotinib reached all the main endpoints of the study, induced clinical remission at the 10th week and remained at 58 weeksDuring the induction and maintenance phase of the study, the incidence of severe infections, shingles, venous thrombosis, pulmonary embolism and gastrointestinal perforation were low in each treatment group